Business Context and Reporting Period
This Form 6-K filing by Can-Fite Biopharma Ltd. covers the month of September 2015. The registrant is a foreign private issuer based in Petach-Tikva, Israel, and files annual reports on Form 20-F.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, or debt figures. The primary financial event disclosed is a capital raise.
- Capital Raised: $9 million in gross proceeds.
- Transaction Type: Definitive agreements with institutional investors.
Material Changes
The material change reported is the execution of definitive agreements to raise $9 million in gross proceeds from institutional investors, announced on September 20, 2015. No comparative financial data or prior period metrics are included in this specific filing.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, future guidance, specific risk factors, or details on contingencies beyond the announcement of the financing. The press release detailing the transaction is incorporated by reference as Exhibit 99.1.
Investor Verification Checklist
- Verify the terms of the definitive agreements with institutional investors (e.g., share price, dilution impact) in the attached press release (Exhibit 99.1).
- Confirm the net proceeds after deducting transaction costs, as only gross proceeds of $9 million are stated.
- Review the company's most recent Form 20-F for baseline liquidity and debt positions prior to this capital raise.